Media ReleasesCellmid Limited

View All Cellmid Limited News


Cellmid Ltd, AGM Presentation 2013

Summary

-  High value cancer therapeutic product pipeline going into phase 1/2a studies in solid tumors;

-  Revenue generating diagnostics division with multiple licenses and regular royalty expected from late 2014;

-  Revenue generating consumer health division with strong growth from emerging markets in 2014 onwards;

-  High value assets underpinned by strong revenue growth.


To view Presentation please download PDF below:

Download this document